This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The 2023 Almanac results derived from the Global Burden of Disease (GBD) and spanning 1990 to 2022, were recently published in the Journal of American College of Cardiology. 2023 Dec, 82 (25) 2343–2349. The post Global Trends in Cardiovascular Diseases: Insights from the 2023 Almanac appeared first on Cardiology Update.
In today’s society, the prevalence of obesity has become a significant concern. have obesity, and this rate has increased by more than 10 percentage points in the past two decades. Understanding the prevalence of obesity is crucial in comprehending why events like Healthy Weight Week are essential. of adults in the U.S.
Obesity is one of the world’s biggest health crisis and only seems to be getting worse. For over 50 years, the rates of obesity have continued to rise worldwide 1. The most recent data on obesity has shown a decline for the first time in a very long time. Between 2020 and 2023, the rates of obesity dropped by about 2% 2.
For over 50 years, rates of those who are overweight or obese have been rising rapidly. Despite the rise in obesity rates, the growing recognition of it as a global problem and the astronomical sums of money we spend on addressing it, the tide continues to rise. That is until now. The answer is… eye wateringly well.
To tackle this problem, researchers compared Veterans Affairs data on 2 million T2D patients (2017-2023) taking either GLP-1s , DPP4is, SGLT2is, or usual care antihyperglycemics over a 3.68 That said, it could serve as an early look into the long-term health outcomes of using GLP-1s to treat obesity and T2D. year follow-up.
Obesity, a pervasive health concern, has been identified as a significant risk factor for ATAAD, introducing unique surgical challenges that can influence postoperative outcomes. Based on BMI (WS/T 428-2013), patients were categorized into normal weight, overweight, and obese. Results The average age of the cohort was 50.1 ± 11.2
The meeting, held at the Queen Elizabeth II Centre, London, on 30th November and 1st December 2023, offered thought-provoking plenary sessions, focused masterclasses, a new ‘technology in action’ demonstration area, plus a number of high-quality poster presentations. Dr Aaron Henry reports highlights from the meeting.
The Global Burden of Disease data (2023) highlights a grim reality: while high-income countries have seen some success in managing CVD, LMICs now account for most CVD-related deaths. This imbalance is partly due to limited healthcare access, fewer preventive resources, and challenges in addressing risk factors such as obesity and diabetes.
The AHA 2023 Scientific Sessions are officially complete. Prevention & Detection – Boosted by GLP-1 obesity buzz and the fact that cardiovascular outcome trends have been headed in the wrong direction, AHA 2023 placed a greater focus on prevention.
That’s what the field of obesity therapeutics feels like right now. What was once an area of healthcare that had few reliable interventions, this drug class has revolutionised the management of excess weight and obesity. Subscribe now 1 [link] 2 [link] 3 Retatrutide Phase 2 Obesity Trial Investigators. 2023 Nov 11.
Can you please explain the concept of an obesity paradox? Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. 2, 3] This association is more pronounced for those with class I obesity, which is a body mass index (BMI) between 30-35 kg/m2.
Cardiometabolic conditions – specifically obesity, diabetes and heart disease – disproportionately affect the 60 million people in the U.S. Cardiometabolic Health Congress faculty member, Fátima Rodriguez, MD, MPH, has committed much of her clinical and research efforts to reducing health disparities in Hispanic-American communities.
At the American Heart Association's (AHA) Scientific Sessions 2023, the Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial was presented demonstrating that 2.4mg once weekly subcutaneous semaglutide.
We previously reported that first-pass pulmonary vein (PV) isolation (FPI) is related to the PV isolation (PVI) durability in ablation index (AI) guided catheter ablation for atrial fibrillation (AF) (J Cardiovasc Electrophysiol 2023). Obesity is reported as a worsening factor for atrial tachyarrhythmia (AT) recurrence after AF ablation.
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010618, November 1, 2023. Fasting blood samples collected at the time of the cardiopulmonary exercise test were used to assay obesity-related biomarkers. 1.70) and 1.25 (95% CI, 1.03–1.52), 1.70) and 1.25 (95% CI, 1.03–1.52),
Obesity is one of the biggest global health concerns we face today. Obesity is also a key driver of risk for cardiovascular disease. Although there are many factors linked to obesity, one factor is certain: excess caloric intake leads to an excess in the energy balance. 2023 Jul;4(7):e345-e353. Obesity (Silver Spring).
The impact of severe obesity on weight-based heparin dosing is not well studied. Lower heparin dose (U/kg) was required in obese patients to achieve target ACT. In conclusion, there is significant variability in the therapeutic effect of heparin, with a lower weight-adjusted heparin dose required in obese patients.
Circulation: Heart Failure, Volume 16, Issue 11 , Page e010524, November 1, 2023. The role of obesity in RV dysfunction and adverse outcomes is unclear.METHODS:We examined patients undergoing right heart catheterization between 2005 and 2016 in a hospital-based cohort. P<0.001).
A session at the 18 th Annual Cardiometabolic Health Congress (CMHC), explored the intersection of cardiometabolic conditions such as obesity and insulin resistance with liver disease, beginning with some important new updates on the preferred terms for these diseases. Available at: [link] (Accessed: October 24, 2023). As of the Oct.
The 14 Factors Include: Hearing Loss High LDL cholesterol Less Education Traumatic Brain Injury Depression Social Isolation Hypertension Obesity Smoking Excess Alcohol Diabetes Physical Inactivity Air Pollution Visual Loss Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission When You Intervene Matters.
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. Research has been conducted previously on rtPA exclusion in obese AIS patients as well as AIS patients with a history of smoking [3, 4, 5, 6]. In some cases, the reason for patients' exclusion from rtPA is due to risk factors and comorbidities [1, 2].
Stroke: Vascular and Interventional Neurology, Volume 3, Issue S2 , November 1, 2023. IntroductionClinical risk factors and co‐morbidities in obese male and female ischemic stroke patients with a history of smoking may contribute to differing stroke outcomes.
billion in healthcare venture funding in 2023. These projected trends are driven by an aging, more diverse population, along with an anticipated significant increase in chronic health risk factors including high blood pressure and obesity. “In
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). 2023; Oct;29(10):1412-1451. Epub 2023 Sep 26. 4 Approximately 6.7 million adults in the U.S. 7 Of these patients, about 55% have a LVEF 40%. MPH, FACP, Vice President, US Medical Affairs, Bayer. J Card Fail.
Type 2 diabetes is much more common in those with a BMI in the overweight or obese category but is not uncommon in those who are relatively normal weight. 2023 Oct;11(10):731-742. 2023 Mar 1;6(3):e234989. 2023 Oct, 82 (16) 1583–1594. But what about those with a relatively normal weight? Lancet Diabetes Endocrinol.
Competence in selecting treatments for long-term obesity management rose from 43% pre-test to 95% post-test. Neha Agarwal, PhD, Clinical Director at Cardiometabolic Health Congress , Informa Connect, recently presented significant findings at the 84th American Diabetes Association (ADA) Scientific Sessions.
More steps are linked to: Less obesity. occupation-related physical activity and their associations with obesity. 2023 Apr;7(4):e313-e328. Therefore, even if living longer is not a priority, delaying the onset of a major chronic disease should be. Higher step counts are a reliable way of hitting this goal. Less diabetes.
Visceral Fat & Insulin Resistance While rates of smoking have decreased significantly in recent decades, the rates of obesity and excess visceral fat have increased dramatically 3. Trends in the number of obese and severely obese people by region. Rates of obesity have tripled in the last 60 years. 2024 Jan 14.
The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members.
And of course Ken's comments at the bottom) An elderly obese woman with cardiomyopathy, Left bundle branch block, and chronic hypercapnea presented hypoxic with altered mental status. For more on Torsades de Pointes vs PMVT See My Comment in the October 18, 2023 post and the September 2, 2024 post in Dr. Smith's ECG Blog ).
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research.
The International Journal of Cardiovascular Science (IJCS) is accepting articles for a special thematic issue focusing on cardiometabolic diseases, to be published in September 2023. These factors include obesity, dyslipidemia, hypertension, and insulin resistance — also known as metabolic syndrome.
Written by Pendell Meyers A man in his late 30s with history of hypertension, tobacco use, and obesity presented to the Emergency Department for acute chest pain which started approximately 3 hours prior to arrival, in the setting of a very stressful situation. The pain radiated down both arms, 10/10 in severity.
Overweight/Obesity. Falling into the class of obesity with a BMI of greater than 30 makes this more likely, but so also does having excess visceral fat deposition with significant metabolic consequences at a BMI less than 30. Weight Loss Potential With Obesity Medications. ” here is what I tell them. Med Clin North Am.
The etiological risk factors of CVDs are widely known and include dyslipidemia, obesity, diabetes, and chronic cigarette consumption. However, one component that is often underestimated is exposure to heavy metals. The biological perspective explains that different metals play different roles.
This study aims to assess the prevalence of systemic inflammation in the ASCVD population in Spain.MethodsOutpatient electronic medical records from The Health Improvement Network (THIN) database were used to identify patients with ASCVD and a C-reactive protein (CRP) measurement 1 between January 2014 and July 2023 in Spain.
New obesity medications such as GLP-1 agonists have shown significant reductions in weight in those with a prior heart attack. JACC Volume 79, Issue 17 , 3 May 2022, Pages 1690-1700 9 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. 2023 Nov 11. Br J Gen Pract. 2018 Mar;68(668):151-152. N Engl J Med.
BackgroundIn 2023, the American Heart Association defined the concept of cardiovascularkidneymetabolic (CKM) syndrome as a health disorder ascribed to connections among obesity, diabetes, chronic kidney disease, and cardiovascular disease. Journal of the American Heart Association, Ahead of Print.
For instance, a pediatric provider may be only interested in topics pertaining to childhood obesity. They could find resources and education focused on that condition within both the Obesity Management and Pediatrics hubs. ” Learners can see some of the CMHC experts in person on Aug.
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
In the early 1970’s a group of 106 severely obese patients were put on a diet that resulted in an average weight loss of 63 Kg (139 lbs) over about one year 2. 2 Treatment of massive obesity with rice/reduction diet program. Lancet Vol 389 April 29, 2017 6 Retatrutide Phase 2 Obesity Trial Investigators. Diabetologia.
Another study published in January 2023 in the Journal of the American Heart Association evaluated data from 593, 616 young adults, and found that depression and poor mental health are associated with premature CVD as well as suboptimal cardiovascular health (CVH). 2023 Jul 5;11(7):1903. JAMA Netw Open. 2021;4(12):e2138920.
Methods:This retrospective analysis of a systemwide stroke registry analyzed patients with ischemic stroke admitted January 2016 to September 2023. This study examines potential contributors to disparities in IVT administration in a large Western healthcare system overall and by state (AK, CA, OR, TX and WA).Methods:This received IVT.
For ICM patients who are at the highest risk of AF detection (those with left atrial enlargement, heart failure , obesity, or prolonged QRS), the cost per QALY is reduced even further to $22,016. “In Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. 147,8 (2023): e93-e621.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content